

What's New in TIL Therapy for Melanoma: A Patient Perspective

Watch this webinar by the Melanoma Research Alliance on tumor-infiltrating lymphocyte (TIL) therapy for skin cancer.

May 18, 2026 By [Melanoma Research Alliance](#)

By Renee Orcione, Associate Director, Communications and Engagement

On May 4, Melanoma Research Alliance (MRA) hosted an installment of our patient-focused Meet Up webinar series called “TIL Therapy for Melanoma: A Patient Perspective and What’s New in Research.”(You can watch the session above or [on YouTube](#).)

The session featured Dr. Ravi Amaravadi of the University of Pennsylvania, a leading physician-scientist in melanoma research and early-phase clinical trials, alongside patient advocate Rob Ricker, in conversation with MRA’s Director of Communications and Engagement, Dana Deighton. The discussion explored how tumor-infiltrating lymphocyte (TIL) therapy is changing the treatment landscape for advanced melanoma and what patients and caregivers can expect when considering this highly personalized form of immunotherapy.

Dr. Amaravadi provided an overview of how TIL therapy works, explaining the process of harvesting and expanding a patient’s own immune cells to help target and destroy melanoma. He also discussed the significance of TIL therapy as the first FDA-approved cellular therapy for a solid tumor, highlighted ongoing research efforts, and shared insights into how investigators are working to improve outcomes and expand the use of TIL therapy across melanoma and other cancers.

Rob Ricker offered a personal perspective on navigating treatment as one of the first commercial TIL therapy recipients at UPenn, sharing his experience throughout the treatment process and the importance of support from caregivers and experienced care teams.

The discussion focused on what patients and families should know about TIL therapy in practice, including key considerations such as:

- How TIL therapy works, including surgical tumor resection, lymphocyte expansion in the lab, chemotherapy preparation, TIL infusion, and recovery

- Patient eligibility for TIL therapy, particularly for those with stage IV or unresectable stage III melanoma who have already received immunotherapy and, when applicable, targeted therapy
- The importance of treatment at experienced, certified centers, along with the role of caregiver support, physical preparation, and emotional readiness throughout the treatment process
- Ongoing research efforts aimed at improving TIL therapy, including earlier use in treatment, and expanding applications across other cancer types

During an interactive Q&A, participants asked thoughtful questions about treatment timelines, side effects, logistical considerations, and how TIL therapy may fit into the broader melanoma treatment landscape.

This webinar offered an informative and encouraging overview of TIL therapy and the latest research developments, helping patients and caregivers better understand this emerging treatment approach and how to navigate conversations with their healthcare teams.

[This post](#) was originally published May 7, 2026, by the [Melanoma Research Alliance](#). It is republished with permission.